Dextromethorphan (DXM) is a dissociative drug hiding in plain sight. Available without a prescription in dozens of countries, present in the medicine cabinets of hundreds of millions of homes, it is the only substance in the world that you can buy at a gas station that will, at sufficient doses, produce full dissociative anesthesia comparable to ketamine. A morphinan-class compound developed in the 1950s by the US Navy and the CIA's MKUltra program as a non-addictive replacement for codeine, DXM was never intended for the strange second life it found: as the most accessible dissociative hallucinogen on Earth, consumed recreationally by generations of teenagers and adults under the name "robotripping."
What makes DXM pharmacologically remarkable is that it is a prodrug. The molecule itself is not the primary actor -- it is metabolized by the liver enzyme CYP2D6 into dextrorphan, a far more potent NMDA receptor antagonist that mediates most of the dissociative effects. But DXM also operates through its own mechanisms: serotonin-norepinephrine reuptake inhibition, sigma-1 receptor agonism, and nicotinic acetylcholine receptor antagonism. This multi-target pharmacology produces an experience that is distinctly different from ketamine or PCP -- warmer, more psychedelic, more serotonergically colored, and with a dose-dependent character so dramatic that the community developed a four-tier "plateau" system to describe it, ranging from mild stimulation and music enhancement at first plateau to full dissociative anesthesia and ego dissolution at fourth.
The safety profile of DXM is dominated by a single, critical fact: the drug itself is relatively safe, but most products containing it are not. Over-the-counter cough formulations frequently combine DXM with acetaminophen, guaifenesin, or antihistamines -- substances that are harmless at therapeutic doses but potentially lethal at the doses required for dissociative effects. Acetaminophen liver toxicity is the leading cause of DXM-related medical emergencies and deaths, and it is entirely preventable. A second critical variable is CYP2D6 polymorphism: approximately 5-10% of Caucasian populations are poor metabolizers of this enzyme, meaning they convert DXM to dextrorphan much more slowly, experience dramatically intensified effects, and face higher risk of serotonin toxicity. In 2022, the FDA approved Auvelity (DXM combined with bupropion, a CYP2D6 inhibitor) for major depressive disorder, formally recognizing what the recreational community had long observed: DXM's NMDA antagonism and sigma-1 agonism have genuine antidepressant potential.
DXM occupies a unique cultural position as perhaps the most extensively community-documented dissociative substance in existence. The "DXM FAQ," compiled in the late 1990s, was one of the earliest comprehensive harm reduction documents for any recreational drug. The plateau dosing framework, the "week per plateau" spacing rule, the 50-trip limit theory, and the detailed mapping of CYP2D6 pharmacogenomics into practical dosing advice all represent genuine community-generated pharmacological knowledge that predates formal clinical interest by decades.
Safety at a Glance
High Risk- The Single Most Important Rule: DXM-Only Products
- Guaifenesin -- causes severe nausea and vomiting, kidney stress at high doses
- Toxicity: Acute Toxicity of DXM Alone DXM in isolation has a relatively wide therapeutic index compared to most recreational di...
- Dangerous with: Alcohol, Desomorphine, GBL, GHB, 25x-NBOMe, 2C-T-x, Cocaine (+5 more)
- Overdose risk: The danger of DXM overdose depends critically on what was consumed. An overdose on DXM-only produ...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 8 hrs – 12 hrsHow It Feels
The onset is slow and unmistakable. Thirty to sixty minutes after swallowing the capsules or drinking the syrup -- which tastes exactly as bad as everyone warned you it would -- a warmth begins spreading from the stomach outward. There is often nausea during this phase, sometimes intense enough to make you question the entire enterprise. Your stomach rolls. You might vomit. Many people do. But if the dose stays down, the first sign that it is working arrives as a subtle rearrangement of how your body feels in space: lighter, slightly detached, as though the distance between your mind and your limbs has increased by a fraction of an inch.
At first plateau, the experience is surprisingly pleasant and functional. A gentle stimulation lifts the mood. Music -- and this cannot be overstated -- becomes extraordinary. Familiar songs reveal structural layers you have never noticed. Basslines acquire physical presence. Melodies carry emotional weight that borders on overwhelming. The community calls this DXM's signature gift, and it is real: no other dissociative enhances music with quite this intensity at low doses. Your body feels light and slightly numb. Walking has a characteristic floaty quality that the community calls "robo-walking" -- you are moving normally but it feels like your legs are operating on a slight delay.
At second plateau, the dissociation announces itself. The world takes on a dreamlike quality -- you are present but watching from behind glass. Closed-eye visuals emerge: flowing landscapes, soft geometric patterns, abstract imagery that responds to music. The euphoria deepens into something almost empathogenic, a warm, serotonergic glow that distinguishes DXM from the cold clarity of ketamine. Conversations become strange -- you can speak, but the words feel like they are coming from somewhere else. Time dilates profoundly. Five minutes can feel like an hour. The body is numb and slightly heavy, and walking becomes genuinely difficult -- the "robo-walk" is no longer subtle but a full, stumbling, ataxic gait.
Third plateau is where DXM becomes a different substance entirely. The dissociation is deep and total. Your body is remote, a distant machine that you can barely operate. Vision fragments into dark, maze-like corridors. Thought patterns loop and fracture. The internal landscape becomes vivid and hallucinatory -- entire worlds unfold behind closed eyes, populated by structures and entities that feel meaningful in ways you cannot articulate. Music at this level is no longer an enhancement but an architecture, building vast imaginary spaces around you. Many people cannot walk. Communication is nearly impossible. The experience is dark, heavy, and profoundly disorienting in a way that users consistently describe as qualitatively different from ketamine's sterile, clinical dissociation.
Fourth plateau -- which requires doses that carry real medical risk -- produces full dissociative anesthesia: complete disconnection from the body, the environment, and the self. Users report experiences of ego death, infinite spaces, encounters with what feel like fundamental aspects of consciousness, and total amnesia for portions of the experience. The return from fourth plateau is long -- eight to twelve hours before baseline, with a residual fog that can last into the next day.
The afterglow is variable. Some people wake the next morning with a pleasant clarity, a reflective openness, and a lingering appreciation for music. Others feel drained, cognitively fogged, and emotionally flat. Heavy or frequent use produces a characteristic "DXM hangover" -- a brittle, depersonalized feeling that the community warns can persist for days. The nausea, the long duration, and the next-day fog are the price of admission, and they are why DXM's recreational appeal, while real, is self-limiting for most people.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(35)
- Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Changes in felt bodily form— Changes in felt bodily form is the experience of one's body feeling as though it has altered its phy...
- Constipation— A slowing or cessation of bowel movements resulting in difficulty passing stool, commonly caused by ...
- Cough suppression— A decreased desire and need to cough, medically known as antitussive action, which can also allow in...
- Decreased libido— Decreased libido is a diminished interest in and desire for sexual activity, commonly caused by subs...
- Difficulty urinating— Difficulty urinating, also known as urinary retention, is the experience of being unable to easily p...
- Dizziness— A sensation of spinning, swaying, or lightheadedness that impairs balance and spatial orientation, o...
- Gait alteration— Gait alteration is a noticeable change in the way a person walks and moves through their environment...
- Increased blood pressure— Increased blood pressure (hypertension) is an elevation of arterial pressure above the normal 120/80...
- Increased bodily temperature— Increased bodily temperature (hyperthermia) is an elevation of core body temperature above the norma...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
- Insomnia— A persistent inability to fall asleep or maintain sleep despite physical tiredness, often characteri...
- Itchiness— A persistent, diffuse urge to scratch the skin that arises without any external irritant, most commo...
- Motor control loss— A distinct decrease in the ability to control one's physical body with precision, balance, and coord...
- Muscle relaxation— The experience of muscles throughout the body losing their rigidity and tension, becoming noticeably...
- Muscle twitching— Muscle twitching consists of small, involuntary, localized contractions or tremors within individual...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Nystagmus— Rapid, involuntary oscillating movements of the eyes that cause vision to vibrate and blur, often ma...
- Orgasm suppression— Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite ad...
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Perception of bodily lightness— Perception of bodily lightness is the subjective feeling that one's body has become dramatically lig...
- Physical autonomy— Physical autonomy is the experience of one's body performing actions — from simple tasks like walkin...
- Physical disconnection— A perceptual distancing from one's own physical body that ranges from a subtle sense of numbness or ...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Spatial disorientation— Spatial disorientation is the inability to accurately perceive one's position or orientation within ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
Tactile(1)
- Tactile suppression— A progressive decrease in the ability to feel physical touch, ranging from mild numbness to complete...
Cognitive & Perceptual Effects
Visual(21)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Double vision— The visual experience of seeing a single object as two separate, overlapping images, similar to cros...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Environmental cubism— A visual distortion in which the environment and objects within it appear fragmented into geometric,...
- External hallucination— A visual hallucination that manifests within the external environment as though it were physically r...
- Frame rate suppression— Perception of visual motion as choppy discrete frames rather than smooth continuous flow, resembling...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Magnification— A visual distortion in which objects appear larger or closer than they actually are, as though one's...
- Peripheral vision changes— Alterations in side vision ranging from enhanced peripheral awareness to tunnel vision, with charact...
- Perspective distortions— Distortion of perceived depth, distance, and size of real objects, making things appear closer, furt...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Visual acuity suppression— Vision becomes blurred, indistinct, and out of focus, as though looking through a smudged lens. Fine...
- Visual disconnection— A dissociative visual effect involving a progressive detachment from visual perception, ranging from...
- Visual haze— A translucent fog or haze overlays the visual field, softening the environment and reducing clarity....
- Visual stretching— A visual distortion in which the perceived visual field is elongated or compressed along one axis, s...
Cognitive(40)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Analysis suppression— Analysis suppression is a cognitive impairment in which the capacity for logical reasoning, critical...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Anxiety suppression— A partial to complete suppression of anxiety and general unease, producing a calm, relaxed mental st...
- Cognitive disconnection— Cognitive disconnection is the experience of feeling profoundly detached from one's own thoughts, se...
- Cognitive dysphoria— A cognitive and emotional state of intense dissatisfaction, discomfort, and malaise encompassing fee...
- Cognitive euphoria— A cognitive and emotional state of intense well-being, elation, happiness, and joy that manifests as...
- Cognitive fatigue— Mental exhaustion and difficulty sustaining thought after intense cognitive experiences, common duri...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Creativity enhancement— An increase in the ability to imagine new ideas, overcome creative blocks, think about existing conc...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delirium— Delirium is a serious and potentially dangerous state of acute mental confusion involving disorienta...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depersonalization— A detachment from one's own sense of self, body, or mental processes, as if observing oneself from o...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Derealization— A perceptual disturbance in which the external world feels profoundly unreal, dreamlike, or artifici...
- Disinhibition— A marked reduction in social inhibitions, self-consciousness, and behavioral restraint that manifest...
- Dream potentiation— Enhanced dream vividness, complexity, and recall, often occurring as REM rebound after discontinuing...
- Ego inflation— Grandiose overconfidence and inflated self-importance, opposite of ego death, commonly produced by s...
- Focus suppression— Focus suppression is a diminished capacity to direct and sustain attention on a chosen target — a ta...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Increased sense of humor— A general amplification of one's sensitivity to finding things humorous and amusing, often causing p...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Language suppression— A diminished ability to formulate, comprehend, or articulate language, ranging from difficulty findi...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Motivation suppression— Motivation suppression is a state of diminished drive and willingness to engage in goal-directed beh...
- Music appreciation enhancement— A profound enhancement of one's enjoyment and emotional connection to music, making songs feel deepl...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Panic attack— A panic attack is a discrete episode of acute, overwhelming fear or terror that arises suddenly and ...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Personal meaning enhancement— Personal meaning enhancement is a state in which everyday events, coincidences, song lyrics, environ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Rejuvenation— A renewed sense of physical vitality, mental freshness, and emotional restoration that can emerge du...
- Sleepiness— A progressive onset of drowsiness, heaviness, and the desire to sleep that pulls the individual towa...
- Thought deceleration— The experience of thoughts occurring at a markedly reduced pace, as if the mind has been placed into...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Auditory(5)
- Auditory distortion— Auditory distortion is the experience of sounds becoming warped, pitch-shifted, flanged, or otherwis...
- Auditory enhancement— Auditory enhancement is a heightened sensitivity and appreciation of sound in which music, voices, a...
- Auditory hallucination— Auditory hallucination is the perception of sounds that have no external source — hearing music, voi...
- Auditory misinterpretation— Auditory misinterpretation is the brief, spontaneous misidentification of real sounds as entirely di...
- Auditory suppression— A dampening of auditory perception in which sounds become muffled, distant, and reduced in both volu...
Multi-sensory(4)
- Gustatory hallucination— Gustatory hallucinations are phantom taste experiences in which distinct flavors manifest in the mou...
- Memory replays— Memory replays are vivid, multisensory re-experiences of past events that go far beyond normal recal...
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
- Synaesthesia— Stimulation of one sense triggers involuntary experiences in another — seeing sounds as colors, tast...
Transpersonal(4)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Spirituality enhancement— A profound intensification of spiritual feelings, mystical awareness, and a sense of sacred connecti...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Prodrug Metabolism and CYP2D6
DXM's dissociative effects are primarily mediated not by the parent molecule but by its metabolite dextrorphan (DXO), produced via O-demethylation by the cytochrome P450 enzyme CYP2D6. Dextrorphan is a substantially more potent NMDA receptor antagonist than DXM itself while being less active as a serotonin reuptake inhibitor and sigma agonist. A second metabolic pathway via CYP3A4 produces 3-methoxymorphinan, which has local anesthetic properties but minimal psychoactive contribution. Both metabolites converge on 3-hydroxymorphinan, which shows neuroprotective activity in preclinical models.
The CYP2D6 step is the pharmacological bottleneck that determines the character of the DXM experience. Poor metabolizers (5-10% of Caucasian populations, with different prevalence across ethnicities) clear DXM far more slowly, resulting in higher DXM-to-DXO ratios, greater serotonergic and sigma receptor engagement, more intense and longer-lasting effects, and significantly elevated risk of serotonin syndrome. This is not a theoretical concern -- community reports consistently describe poor metabolizers being blindsided by unexpectedly intense experiences from doses that would be moderate for normal metabolizers. CYP2D6 inhibitors (including bupropion, fluoxetine, and paroxetine) produce a pharmacological equivalent of poor metabolizer status in anyone.
NMDA Receptor Antagonism
The core dissociative mechanism. Dextrorphan blocks the ion channel of the NMDA glutamate receptor as a non-competitive antagonist, disrupting excitatory signaling throughout the central nervous system. This produces the characteristic disconnection from sensory input, the feeling of removal from the body, the ego dissolution at high doses, and the anesthetic properties. The potency is intermediate between nitrous oxide and ketamine.
Serotonergic Activity
DXM (but not dextrorphan) is a moderately potent serotonin-norepinephrine reuptake inhibitor. This is the mechanism behind its antitussive action, but at recreational doses it produces the empathogenic warmth, mood elevation, and serotonergic "glow" that distinguishes the DXM experience from ketamine. It is also the source of its most dangerous drug interaction: serotonin syndrome when combined with MAOIs, SSRIs, or SNRIs. This interaction has killed people.
Sigma-1 Receptor Agonism
DXM has significant affinity for the sigma-1 receptor, a chaperone protein involved in neuroplasticity, neuroprotection, and mood regulation. Sigma-1 agonism is believed to contribute to the dreamlike, psychedelic character of DXM -- the quality that users describe as "more visual" and "more trippy" than ketamine. It is also the mechanism targeted by Auvelity (DXM/bupropion) for depression treatment.
Dose-Dependent Pharmacology: The Plateau System
The DXM experience is famously dose-dependent, with qualitatively different states emerging at different dose ranges. This occurs because the relative contributions of NMDA antagonism, serotonergic activity, and sigma agonism shift as plasma concentrations rise:
- First plateau (1.5-2.5 mg/kg): Primarily serotonergic and sigma effects -- stimulation, mood elevation, enhanced music appreciation. Minimal dissociation
- Second plateau (2.5-7.5 mg/kg): NMDA antagonism becomes prominent -- euphoria, closed-eye visuals, mild dissociation, profound music enhancement
- Third plateau (7.5-15 mg/kg): Strong NMDA blockade dominates -- deep dissociation, hallucinations, ego fragmentation, ataxia, significant cognitive impairment
- Fourth plateau (15+ mg/kg): Full dissociative anesthesia -- complete disconnection from body and environment, ego death, experiences comparable to high-dose ketamine holes
Detection Methods
DXM can cause false positive results on standard immunoassay drug screens for PCP (phencyclidine) and sometimes opioids, due to structural similarities. Confirmatory GC-MS testing will not confirm PCP or opioids, resolving the false positive. Some expanded drug panels specifically test for DXM and its metabolite dextrorphan.
In urine, DXM and dextrorphan are detectable for approximately 2-4 days after use, though this varies with dose and individual metabolism (CYP2D6 activity). In blood, DXM is detectable for approximately 24-48 hours. Hair follicle testing for DXM has limited validation but is theoretically possible.
There are no commonly used reagent tests for DXM in harm reduction settings. The Mandelin reagent shows a dark gray-black reaction with DXM. Marquis shows a slight gray reaction. These are not sufficiently specific for reliable identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| Alcohol | Dangerous | — |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| GBL | Dangerous | — |
| GHB | Dangerous | — |
| MDMA | Dangerous | — |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Opioids | Dangerous | — |
| PCP | Dangerous | — |
| 25x-NBOMe | Unsafe | — |
| 2C-T-x | Unsafe | — |
| Cocaine | Unsafe | — |
| DOx | Unsafe | — |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-MeO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-MeO-PCMo | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| Benzodiazepines | Uncertain | — |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 25E-NBOH | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 2C-T | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
DXM's origin story is wilder than most people realize. In the early 1950s, the United States Navy and the CIA's MKUltra program -- the same covert research program that tested LSD on unwitting subjects -- were searching for a non-addictive replacement for codeine as a cough suppressant. Codeine was effective but carried the liabilities of any opioid: dependence, abuse potential, and respiratory depression. Researchers at the Naval Medical Research Institute screened compounds from the morphinan family and identified dextromethorphan -- the dextrorotatory (right-handed) isomer of the methyl ether of levorphanol, a potent opioid. The dextro configuration was the key: it retained the antitussive properties of its parent structure while having minimal affinity for the mu-opioid receptor, making it essentially non-addictive as a cough suppressant.
DXM was patented in 1954 and approved by the FDA in 1958 for over-the-counter sale. Hoffmann-La Roche marketed it as Romilar in tablet form. Almost immediately, recreational use was discovered. By the early 1960s, Romilar abuse was sufficiently widespread that the tablets were pulled from the market in 1973. The pharmaceutical industry's response was to reformulate DXM into liquid cough syrups with unpleasant-tasting inactive ingredients designed to deter recreational consumption -- a strategy that worked about as well as one might expect.
The 1990s brought the internet, and with it came the most significant development in DXM's recreational history: the "DXM FAQ" and the emergence of online harm reduction communities. Compiled by early internet pharmacology enthusiasts, the DXM FAQ was one of the first comprehensive documents to systematically describe a recreational drug's effects, dosing, risks, and pharmacology. The four-plateau dosing framework, the week-per-plateau rule, the CYP2D6 pharmacogenomic considerations, and the warnings about acetaminophen-containing products all originated in these communities and have been validated, to varying degrees, by subsequent clinical and pharmacological research.
DXM abuse surged again in the 2000s, prompting several US states to implement age-restriction laws on DXM-containing product purchases. Pure DXM powder and gel capsule products became available online, somewhat reducing (but not eliminating) the danger from combination products. In 2010, the FDA approved Nuedexta (DXM/quinidine) for pseudobulbar affect, and in 2022, Auvelity (DXM/bupropion) was approved for major depressive disorder -- a milestone that formally validated the community's long-standing observation that DXM has antidepressant properties. The bupropion in Auvelity serves as a CYP2D6 inhibitor, raising DXM plasma levels to maintain its NMDA antagonist and sigma-1 agonist activity at subrecreational doses.
Harm Reduction
The Single Most Important Rule: DXM-Only Products
This cannot be stated forcefully enough. The majority of serious medical emergencies and deaths attributed to "DXM" are actually caused by other active ingredients in combination cough products. Check every label. The only acceptable active ingredient is dextromethorphan (as HBr or polistirex).
- Acetaminophen (paracetamol) -- causes irreversible liver failure at recreational DXM doses. This kills people. If someone has ingested a DXM product containing acetaminophen at recreational doses, seek emergency medical attention immediately even if they feel fine. The antidote (N-acetylcysteine) is only effective within the first 8-12 hours, and liver damage symptoms may not appear for 24-72 hours
- Guaifenesin -- causes severe nausea and vomiting, kidney stress at high doses
- Chlorpheniramine and other antihistamines -- anticholinergic toxicity, seizure risk, cardiac arrhythmias
- Pseudoephedrine/phenylephrine -- cardiovascular emergencies at high doses
Safe options: Robitussin DM (not Multi-Symptom), DXM-only gel capsules (Robafen), Delsym (extended-release polistirex -- note: different pharmacokinetics), or pure DXM powder with a milligram scale.
Start at First Plateau
Your first experience should be a first-plateau dose (1.5-2.5 mg/kg, roughly 100-175 mg for a 70 kg person). This lets you assess your individual sensitivity, particularly whether you might be a CYP2D6 poor metabolizer -- in which case a "normal" dose will hit you dramatically harder than expected. If first plateau feels surprisingly intense, you are likely a poor metabolizer and should adjust all future doses downward significantly.
The "Week Per Plateau" Rule
Community-developed spacing guidance that has held up over decades of collective experience:
- 1 week minimum after a first-plateau experience
- 2 weeks after second plateau
- 3 weeks after third plateau
- 4 weeks (1 month) after fourth plateau
This is not arbitrary -- it reflects observed recovery times for cognition, mood, and organ function. Users who ignore this and dose frequently report persistent cognitive fog, memory impairment, depersonalization, and emotional blunting.
Serotonin Syndrome: The Lethal Combination Risk
DXM is serotonergic. Combining it with the following is potentially fatal:
- MAOIs -- absolute contraindication. Serotonin syndrome can be lethal
- SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine, etc.) -- serotonin syndrome risk. Many people take these daily and do not realize the danger
- MDMA -- high serotonin syndrome risk
- St. John's Wort -- mild MAOI, but enough to be dangerous with DXM
- Tramadol -- serotonergic opioid, seizure threshold lowering, and respiratory depression
Signs of serotonin syndrome: muscle rigidity, hyperthermia, rapid heartbeat, agitation, confusion, diarrhea. This is a medical emergency. Call 911.
CYP2D6 Inhibitor Awareness
Many common medications inhibit CYP2D6 and will dramatically potentiate DXM: bupropion (Wellbutrin), fluoxetine (Prozac), paroxetine (Paxil), quinidine, and others. If you take any of these, standard DXM doses will be far stronger and longer-lasting than expected.
Nausea Management
Nausea is the most common unpleasant effect. Strategies: dose on a mostly empty stomach (light snack 1-2 hours prior), use gel capsules instead of syrup, take 25 mg diphenhydramine 30 minutes before (no more -- higher doses add anticholinergic effects), have ginger available, and accept that some nausea is simply part of the experience.
The 50-Trip Limit
A widely discussed community observation: many long-term DXM users report that after approximately 50 separate experiences, DXM's rewarding and unique effects permanently diminish. Whether this represents genuine neurotoxicity, irreversible NMDA receptor downregulation, or a psychological phenomenon is unknown, but the observation is consistent enough across independent reports to warrant mention. It suggests a lifetime budget of DXM experiences that, once spent, does not replenish.
Toxicity & Safety
Acute Toxicity of DXM Alone
DXM in isolation has a relatively wide therapeutic index compared to most recreational dissociatives. The lethal dose in humans is not well established, but case reports suggest that fatalities from DXM alone (without co-ingestants or dangerous combinations) are exceedingly rare. The primary acute risks at recreational doses are tachycardia, hypertension, hyperthermia, and at extreme doses (above roughly 15-20 mg/kg), seizures and respiratory depression. Serotonin toxicity is a real concern at high doses, particularly in CYP2D6 poor metabolizers or when any serotonergic co-medication is present.
The Acetaminophen Catastrophe
The single most dangerous aspect of recreational DXM use is co-ingestion of acetaminophen from combination products. Acetaminophen is hepatotoxic above approximately 4 grams per day in most adults, and recreational DXM doses from combination syrups can easily deliver 10-20 grams. Acute liver failure from acetaminophen is irreversible without liver transplant in severe cases and may not produce symptoms for 24-72 hours, by which point the damage is done. N-acetylcysteine is an effective antidote but must be administered within 8-12 hours. This is the cause of most DXM-related deaths and is entirely preventable by using DXM-only products.
Chronic Use Effects
Frequent, heavy DXM use over months to years has been associated with persistent cognitive impairment (memory, attention, executive function), depersonalization and derealization that can persist for weeks to months after cessation, emotional blunting, and a characteristic flat affect. A formal survey of dependent DXM users found that over half reported fatigue, apathy, flashbacks, and constipation during the first week of withdrawal. Over a quarter reported insomnia, nightmares, anhedonia, memory impairment, and decreased libido.
Olney's Lesions
Early animal research raised concerns about NMDA antagonist-induced neurotoxicity (Olney's lesions) -- vacuolar changes in certain brain regions observed in rats given high doses of NMDA antagonists. However, oral DXM administration has not been shown to produce these lesions in animal models, and the relevance of rat studies (which used injectable NMDA antagonists at doses far exceeding human recreational use) to human oral DXM consumption is uncertain. This does not mean chronic DXM use is neurologically safe -- the cognitive complaints of heavy users suggest real neural consequences -- but the specific Olney's lesion mechanism is not established for DXM in humans.
The 50-Trip Limit and Permanent Tolerance
A persistent community observation holds that after approximately 50 separate DXM experiences, the substance's rewarding effects permanently diminish. Proposed mechanisms include irreversible NMDA receptor downregulation, chronic glutamatergic upregulation, and sigma receptor desensitization. Whether this represents genuine neurotoxicity or an adaptive tolerance that simply never fully reverses is unknown.
Urinary Tract Effects
Heavy chronic DXM use can produce bladder and urinary tract symptoms similar to those seen with ketamine (urinary frequency, urgency, pelvic pain, hematuria), though generally less severe -- likely because DXM's higher potency per milligram means less total drug passes through the urinary system. These effects are cumulative and dose-dependent.
Serotonin Syndrome
DXM's serotonergic activity makes it uniquely dangerous among dissociatives when combined with other serotonergic drugs. Serotonin syndrome from DXM + MAOI combinations has been fatal. The risk is also significant with SSRIs, SNRIs, MDMA, and tramadol. Symptoms include hyperthermia, muscle rigidity, agitation, rapid heartbeat, and altered mental status. This is a medical emergency requiring immediate treatment.
Addiction Potential
DXM produces moderate physical and psychological dependence with chronic heavy use. Its addiction potential is lower than that of PCP or ketamine partly because the nausea, long duration, and cognitive impairment make compulsive daily use self-limiting for most people -- but a significant minority does develop dependent patterns. Community reports and formal surveys document cases of daily use persisting for months to years, driven by the combination of easy over-the-counter availability, psychological dependence on the dissociative state, and genuine antidepressant effects that users are reluctant to relinquish. Withdrawal from chronic DXM use produces an antidepressant-discontinuation-like syndrome: fatigue, apathy, anhedonia, insomnia, nightmares, flashbacks, constipation, impaired memory, attention deficits, and decreased libido. Over half of surveyed dependent users reported fatigue, apathy, and flashbacks during the first week of abstinence. The withdrawal is not physically dangerous (unlike alcohol or benzodiazepines) but can be psychologically distressing and prolonged, with cognitive and emotional symptoms persisting for weeks to months. Tolerance develops with repeated use and follows multiple mechanisms: NMDA receptor downregulation (reduced receptor density), compensatory glutamatergic upregulation, and hepatic enzyme induction (accelerated metabolism). Tolerance to half baseline resets in approximately 3-7 days; full baseline recovery takes 1-2 weeks. Cross-tolerance exists with all dissociatives. The community has also identified a phenomenon of apparently irreversible permanent tolerance in some heavy long-term users -- the "50-trip limit" -- suggesting that some neuroadaptive changes may not fully reverse. DXM's easy availability as an over-the-counter medication substantially increases its abuse potential relative to controlled dissociatives, and the accessibility is a key risk factor in adolescent use patterns.
Overdose Information
The danger of DXM overdose depends critically on what was consumed. An overdose on DXM-only products is medically serious but rarely fatal in otherwise healthy individuals. An overdose involving acetaminophen-containing products is a medical emergency that can cause irreversible liver failure and death.
Recognizing DXM Overdose
- Extreme agitation, delirium, or unresponsiveness
- Very rapid heartbeat (tachycardia above 150 bpm sustained)
- High blood pressure
- Dangerously elevated body temperature (hyperthermia)
- Seizures
- Muscle rigidity (suggesting serotonin syndrome)
- Severely impaired or absent breathing (at extreme doses)
- Nystagmus (rapid involuntary eye movements)
The Acetaminophen Emergency
If there is any possibility that the ingested product contained acetaminophen, call 911 immediately regardless of how the person appears. Acetaminophen liver toxicity is insidious: the person may feel relatively fine for 24-48 hours while irreversible liver damage progresses. N-acetylcysteine (NAC) is an effective antidote but is most effective within 8 hours of ingestion. Inform emergency responders specifically that acetaminophen may have been co-ingested.
Serotonin Syndrome
If the person is on SSRIs, SNRIs, MAOIs, or has combined DXM with MDMA or tramadol, watch for: muscle rigidity, clonus (rhythmic muscle jerking), hyperthermia, rapid heartbeat, agitation, and confusion. This is serotonin syndrome and requires emergency treatment. Cyproheptadine is the specific antidote used in emergency settings.
Emergency Response
- Call 911. Be honest about what was consumed -- medical staff need accurate information, and Good Samaritan laws protect callers in most jurisdictions
- If the person is unconscious, place them in the recovery position (on their side) to prevent aspiration of vomit
- If they are seizing, protect their head but do not restrain them or put anything in their mouth
- If breathing is absent or very slow, begin CPR
- Monitor body temperature -- DXM overdose can cause dangerous hyperthermia
- Do not leave the person alone
When to Call 911
Call emergency services if any of the following are present: seizures, unresponsiveness, sustained heart rate above 150 bpm, chest pain, very high body temperature, signs of serotonin syndrome, severely slowed breathing, or any suspicion of acetaminophen co-ingestion.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | develops with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Dextromethorphan (DXM) is widely available as an over-the-counter cough suppressant in most countries, though its potential for recreational misuse has led to increasing restrictions in several jurisdictions.
- United States: Not a federally scheduled substance. Available over-the-counter in most states, though many states and retailers require purchasers to be 18 or older. Some states have enacted laws specifically targeting DXM sales to minors. The FDA has considered but not pursued federal scheduling.
- United Kingdom: Available over-the-counter in pharmacies. Sale is restricted to pharmacy-only (not general retail), and pharmacists may refuse sale if misuse is suspected.
- Australia: Available over-the-counter in pharmacies as a Schedule 2 (Pharmacy Medicine) product. Pharmacist supervision is required for purchase.
- Canada: Not a controlled substance under the CDSA. Available over-the-counter without restriction.
- Russia: Classified as aSchedule III controlled substance, making it one of the few countries to formally schedule DXM. Possession and sale outside of approved medical channels carry criminal penalties.
- Sweden: DXM-containing products were withdrawn from the market due to concerns over recreational abuse and have not been reintroduced.
- China: Reclassified DXM-containing compound preparations asClass II psychotropic drugs in September 2024, significantly tightening controls on what had previously been a widely abused OTC product. Single-ingredient DXM preparations had already been restricted earlier.
- Germany: Available over-the-counter in pharmacies. Not scheduled under the BtMG (Narcotics Act).
- France: Available by prescription only since 2017, following concerns about recreational misuse among young people.
- Denmark: Available by prescription only.
- Poland: Available over-the-counter, but the purchaser must be over 18 and cannot buy more than 360mg of the substance at a single pharmacy.
Experience Reports (6)
Tips (10)
The single most important rule with DXM: the ONLY active ingredient should be dextromethorphan (HBr or polistirex). Products containing acetaminophen (Tylenol) will destroy your liver at recreational DXM doses. Guaifenesin will make you violently ill. Antihistamines add dangerous sedation. Read the label carefully every single time.
ONLY use products containing DXM as the SOLE active ingredient. Guaifenesin causes severe vomiting. Acetaminophen will destroy your liver and can be fatal. Chlorpheniramine is cardiotoxic. Read the label carefully.
DXM is a serotonin reuptake inhibitor in addition to being an NMDA antagonist. Combining it with SSRIs, SNRIs, MAOIs, tramadol, or MDMA can cause potentially fatal serotonin syndrome. If you take any serotonergic medication, DXM is off-limits. This is not a theoretical risk — there are documented fatalities.
DXM is a serotonin reuptake inhibitor. NEVER combine with SSRIs, SNRIs, MAOIs, or any serotonergic drugs. Serotonin syndrome is a medical emergency and this combination has caused deaths.
DXM has four distinct dose-dependent "plateaus": 1st (100-200mg) is mildly euphoric and stimulating, 2nd (200-500mg) produces dissociation and music enhancement, 3rd (500-900mg) causes significant dissociation and out-of-body experiences, 4th (900mg+) is near-anesthetic. Doses are highly weight-dependent — use a DXM calculator and start at 1st plateau.
About 5-10% of Caucasians are poor CYP2D6 metabolizers. For these individuals, a normal recreational dose of DXM can produce effects equivalent to a massively higher dose, potentially causing serotonin syndrome or dangerous sedation. Start with a very low test dose (60-90mg) your first time to check for enzyme deficiency.
Community Discussions (12)
A researcher questions the scientific validity of sigma receptor research, noting that despite sigma-1 agonism being implicated in numerous disparate biological processes, mouse knockout models appear normal and the mechanistic evidence is weak. They ask for help understanding what makes sigma receptors therapeutically significant beyond apparent pleiotropy.
A user poetically describes their first DXM experience under an oak tree as a transformative, spiritually significant moment that wiped their sense of self and connected them to ancestral consciousness. They invite others to share their own dissociative discovery moments.
A user describes noticing improved mood, motivation, and focus on days they took DXM (via DayQuil) while on bupropion for depression, linking the effect to DXM's NMDA antagonist and sigma-1 agonist mechanisms similar to ketamine's antidepressant action. They reference a published study on DXM as a possible antidepressant bridging molecule.
A 34-year-old with a decade-old psychedelic history describes unexpectedly intense effects after smoking weed combined with Lexapro, Melatonin, and Ativan, leading to what they believe was an intense dissociative or psychedelic-like experience while watching a film. They seek discussion about whether cannabis can trigger such experiences in some people.
DXM products with multiple active ingredients (like guaifenesin, acetaminophen, or pseudoephedrine) can be dangerous or even fatal at recreational doses, so only products with DXM as the sole active ingredient should be used. Users should calculate their target dose using a DXM calculator based on body weight and avoid frequent use.
A first-time DXM user takes 225mg (approximately second plateau for their weight) of Benylin syrup with a diphenhydramine antiemetic, describes an unremarkable come-up before nausea sets in, then vapes cannabis to manage the nausea before proceeding through the experience. The report covers the early phases with focus on administration and onset.
A person struggling with depression, anhedonia, and social anxiety describes feeling mentally clearer on low doses (100-200mg) of DXM, as if a mental fog is lifted, despite not feeling high. They express difficulty finding employment and managing anxiety, and ask for life advice.
A user reflects on how their early DXM use at age 18 created a conflict between their relationship and their new identity as a drug explorer, ultimately leading to the breakdown of a long-term relationship. They describe feeling like they were living two separate lives and examine their own responsibility for how they handled the situation.
See Also
Similar by Effects
Same Class
References (5)
- Dextromethorphan Vault - Erowid
Erowid experience vault for Dextromethorphan
erowid - Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- PubChem: Dextromethorphan
PubChem compound page for Dextromethorphan (CID: 5360696)
pubchem - Dextromethorphan - TripSit Factsheet
TripSit factsheet for Dextromethorphan
tripsit - Dextromethorphan - Wikipedia
Wikipedia article on Dextromethorphan
wikipedia
Gallery